A Phase I, Single-Centre, Randomised, Placebo and Positive- Controlled, Parallel-Group Study of the Electrocardiographic Effects of TA-8995 in Healthy Male and Female Subjects.
Latest Information Update: 19 Feb 2015
Price :
$35 *
At a glance
- Drugs Obicetrapib (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
- Sponsors Xention
- 15 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Jan 2014 New trial record